ClinicalTrials.gg

Program

bomedemstat

Also written as “Bomedemstat”.

Its studies are mostly in Thrombocythemia, Essential · Polycythemia Vera · Hepatic Insufficiency · Primary Myelofibrosis · Leukemia, Myeloid, Acute, led by Merck.

Furthest: phase 3, since Oct 6, 202311 company-led studies, 4 open or runningNext primary completion: Jul 14, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck114 open or runningphase 3since Oct 6, 2023Jul 12, 2016Jul 14, 2027phase 3 · NCT06079879
  • Named in Merck’s own pipeline as bomedemstat (MK-3543), phase 3, as of Nov 2, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 12, 2016First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT02842827 · 45 enrolled · Australia
  2. Apr 18, 2017Phase 2 study in Primary MyelofibrosisNCT03136185 · 90 enrolled · United States, Australia, Germany and more
  3. Jan 15, 2020Phase 2 study in Thrombocythemia, EssentialNCT04254978 · 73 enrolled · United States, Australia, Germany and more
  4. Aug 31, 2021Phase 2 study in Thrombocythemia, EssentialNCT05223920 · 81 enrolled · United States, Australia, Germany and more
  5. Sep 20, 2022Phase 2 study in Polycythemia VeraNCT05558696 · 20 enrolled · United States, Australia, United Kingdom
  6. Oct 6, 2023Phase 3 study in Thrombocythemia, EssentialNCT06079879 · 340 enrolled · United States, Argentina, Australia and more
  7. Apr 2, 2024Phase 3 study in Thrombocythemia, EssentialNCT06351631 · 400 planned · United States, Australia, Hong Kong and more
  8. Jun 7, 2024Phase 3 study in Thrombocythemia, EssentialNCT06456346 · 300 enrolled · United States, Argentina, Australia and more
  9. Sep 11, 2024Phase 1 study in HealthyNCT06596668 · 16 enrolled · United States
  10. Jun 25, 2025Phase 1 study in Hepatic InsufficiencyNCT07049939 · 9 enrolled · United States
  11. Jul 20, 2026Phase 3 study in Polycythemia VeraNCT07722611 · 380 planned · United States, Canada, Israel

Ahead

  1. Jul 14, 2027Primary completion: phase 3 study in Thrombocythemia, EssentialNCT06079879
  2. Sep 28, 2027Primary completion: phase 3 study in Thrombocythemia, EssentialNCT06456346
  3. Jun 25, 2032Primary completion: phase 3 study in Polycythemia VeraNCT07722611
  4. Dec 4, 2034Primary completion: phase 3 study in Thrombocythemia, EssentialNCT06351631

TargetBeta

“An orally available, irreversible inhibitor of lysine-specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, bomedemstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of…”NCIt, read by Claude
“An orally available, irreversible inhibitor of lysine-specific demethylase 1 (LSD1), ”NCIt, by rule
“Lysine-specific histone demethylase 1 inhibitor”ChEMBL 37, by rule

Other programs on KDM1A

ProgramCompanyFurthest phaseStudies
LSD1 Inhibitor EXS74539ruleexscientia-ai-ltd-a-wholly-owned-subsidiary-of-recursion-phaphase 11

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07722611Polycythemia Vera · United States, Canada, Israel3RecruitingJun 25, 2032380
NCT07049939Hepatic Insufficiency · United States1CompletedFeb 17, 20269
NCT06596668Healthy · United States1CompletedFeb 5, 202516
NCT06456346Thrombocythemia, Essential · United States, Argentina, Australia and more3Active, not recruitingSep 28, 2027300
NCT06351631Thrombocythemia, Essential · United States, Australia, Hong Kong and more3RecruitingDec 4, 2034400
NCT06079879Thrombocythemia, Essential · United States, Argentina, Australia and more3Active, not recruitingJul 14, 2027340
NCT05558696Polycythemia Vera · United States, Australia, United Kingdom2CompletedMar 24, 202520
NCT05223920Thrombocythemia, Essential · United States, Australia, Germany and more2CompletedAug 22, 202481
NCT04254978Thrombocythemia, Essential · United States, Australia, Germany and more2CompletedMar 23, 202373
NCT03136185Primary Myelofibrosis · United States, Australia, Germany and more2CompletedMar 8, 202290
NCT02842827Leukemia, Myeloid, Acute · Australia2CompletedOct 30, 201845

How it is read

Names in the registry

  • “Bomedemstat”, 9 entries
  • “bomedemstat”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.